Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCR-188 in overweight or obese volunteers
NCT06845943Phase 1Suspended
- Sponsor
- Helicore Biopharma
- Start
- Mar 2025
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing HCR-188 with Placebo (2 arms). Primary endpoints: Treatment-emergent Adverse Events at 20 weeks, Treatment-emergent Adverse Events Resulting in Treatment Discontinuation at 20 weeks and 3 more. Started Mar 2025; status: suspended.
02
Drugs
HCR-188
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06845943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06845943.